Pharma Mar, S.A.

BME:PHM 株式レポート

時価総額：€593.8m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Pharma Mar マネジメント

マネジメント 基準チェック /14

Pharma Mar'sの CEO はJose Fernandez Sousa-Faroで、 Jan1986年に任命され、 の在任期間は 38.42年です。 は、会社の株式の6.32%を直接所有しており、その価値は€ 37.57M 。経営陣と取締役会の平均在任期間はそれぞれ13.3年と2年です。

主要情報

Jose Fernandez Sousa-Faro

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間38.4yrs
CEOの所有権6.3%
経営陣の平均在職期間13.3yrs
取締役会の平均在任期間2yrs

経営陣の近況

Recent updates

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09
Is Pharma Mar (BME:PHM) Using Too Much Debt?

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08
Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31
Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08
Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14
Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19
Is Pharma Mar (BME:PHM) A Risky Investment?

CEO（最高経営責任者

Jose Fernandez Sousa-Faro

38.4yrs

在職期間

€294,000

報酬

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jose Fernandez Sousa-Faro
Founder38.4yrs€294.00k6.32%
€ 37.5m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kデータなし
Juan Carretero
Founderno dataデータなしデータなし
María de Francia Caballero
Chief Financial Officer24.4yrsデータなしデータなし
José Moreno Martinez-Losa
Head of Capital Markets & Investor Relations9.4yrsデータなしデータなし
Juan Pulido
General Counsel & Secretary of the Board of Directors4.8yrsデータなしデータなし
Sandra Sanchez
Global Compliance Head4.1yrsデータなしデータなし
Lara Vadillo
Communication Directorno dataデータなしデータなし
Belén Veramendi
Director of Corporate Development2.4yrsデータなしデータなし
Luis Cuenca
Director of Human Resources & IT20.9yrsデータなしデータなし
Luis Mora Capitan
Managing Director of Oncology & Virology Business Units17.2yrsデータなしデータなし
Pascal Besman
Chief Operating Officer of Pharmar U.S.no dataデータなしデータなし

13.3yrs

平均在職期間

経験豊富な経営陣: PHMの経営陣は経験豊富で経験豊富です（平均在職期間は13.3年）。

取締役

名称ポジション在職期間報酬所有権
Jose Fernandez Sousa-Faro
Founderno data€294.00k6.32%
€ 37.5m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kデータなし
Eduardo Serra Rexach
Independent Other External Director3.4yrs€35.00k0.062%
€ 370.7k
M. Solchaga Catalan
Independent Other External Directorno data€35.00kデータなし
Montserrat Andrade Detrell
Proprietary Directorno data€34.00k5.41%
€ 32.1m
Blanca Hernandez Rodriguez
Independent Director5.4yrsデータなしデータなし
Maria Sandra Mera
Representative Proprietary Director3.5yrsデータなしデータなし
Rosa Maria Alonso
Independent Director2yrsデータなし0.0010%
€ 6.2k
Mariano Rodriguez
Independent Coordinating Director2yrsデータなしデータなし
Emiliano Aller
Independent Director2yrsデータなしデータなし
Fernando Santos
Independent Other External Directorno dataデータなしデータなし
Soledad Miranda
Independent Director1.1yrsデータなしデータなし

2.0yrs

平均在職期間

経験豊富なボード: PHMの 取締役会 は 経験豊富 ではない ( 2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。